Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial

[1]  M. V. Van Bockstal,et al.  Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine , 2022, Cancers.

[2]  F. Feng,et al.  Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor‐positive breast cancer: A network meta‐analysis , 2019, Journal of cellular physiology.

[3]  N. Taira,et al.  Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study , 2018, Breast Cancer Research and Treatment.

[4]  H. Mukai,et al.  95OEfficacy and safety of palbociclib plus endocrine therapy in women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the Asia-Pacific region: Data from PALOMA-2 and -3 , 2017 .

[5]  J. Guan,et al.  Breast Cancer: Multiple Subtypes within a Tumor? , 2017, Trends in cancer.

[6]  M. Dowsett,et al.  Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. , 2017, The oncologist.

[7]  B. Ács,et al.  Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy , 2017, Diagnostic Pathology.

[8]  C. Barrios,et al.  Optimal management of hormone receptor positive metastatic breast cancer in 2016 , 2015, Therapeutic advances in medical oncology.

[9]  M. Goetz,et al.  Landscape of Neoadjuvant Therapy for Breast Cancer , 2015, Annals of Surgical Oncology.

[10]  R. O'Regan,et al.  Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer , 2013, Front. Oncol..

[11]  John M S Bartlett,et al.  An international Ki67 reproducibility study. , 2013, Journal of the National Cancer Institute.

[12]  S. Fox,et al.  Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer , 2013, British Journal of Cancer.

[13]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[14]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[15]  W. Miller,et al.  Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score , 2011, British Journal of Cancer.

[16]  J. Dering,et al.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.